Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
Neuro-Oncology · 14.02.2023 · 25 (2) · 339-350
DOI: 10.1093/neuonc/noac173 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, online erschienen am 15.07.2022. Verfasst von Andrew B Lassman und 31 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospita…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 173-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Cancer Institute, National Institutes of Health, ABB.
Abstract (Originalsprache)
Background
Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised of a monoclonal antibody that binds activated EGFR (overexpressed wild-type and EGFRvIII-mutant) linked to a microtubule-inhibitor toxin in EGFR-amp GBMs.
Methods
In this phase III trial, adults with centrally confirmed, EGFR-amp newly diagnosed GBM were randomized 1:1 to radiotherapy, temozolomide, and depatux-m/placebo. Corneal epitheliopathy was treated with a combination of protocol-specified prophylactic and supportive measures. There was 85% power to detect a hazard ratio (HR) ≤0.75 for overall survival (OS) at a 2.5% 1-sided significance level (ie traditional two-sided p ≤ 0.05) by log-rank testing.
Results
There were 639 randomized patients (median age 60, range 22–84; 62% men). Prespecified interim analysis found no improvement in OS for depatux-m over placebo (median 18.9 vs. 18.7 months, HR 1.02, 95% CI 0.82–1.26, 1-sided p = 0.63). Progression-free survival was longer for depatux-m than placebo (median 8.0 vs. 6.3 months; HR 0.84, 95% confidence interval [CI] 0.70–1.01, p = 0.029), particularly among those with EGFRvIII-mutant (median 8.3 vs. 5.9 months, HR 0.72, 95% CI 0.56–0.93, 1-sided p = 0.002) or MGMT unmethylated (HR 0.77, 95% CI 0.61–0.97; 1-sided p = 0.012) tumors but without an OS improvement. Corneal epitheliopathy occurred in 94% of depatux-m-treated patients (61% grade 3–4), causing 12% to discontinue.
Conclusions
Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. No new important safety risks were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.
- Herbert Irving Comprehensive Cancer Center, New York, New York, USA.
- RTOG Foundation Statistics and Data Management Center, American College of Radiology, Philadelphia, Pennsylvania.
- Department of Radiation Oncology (in Neurological Surgery), Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian Hospital, New York, New York, USA.
- Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
- Cancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.
ORCID-Profile: Andrew B Lassman, Kenneth Aldape, Matthias Preusser, Madan G Kundu, Giuseppe Lombardi
Förderung
- National Cancer Institute
- National Institutes of Health
- ABB
- AbbVie
- Clough
Zitieren
APA
Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., …, & Mehta, M. P. (2023). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339-350. https://doi.org/10.1093/neuonc/noac173
Vancouver
Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology. 2023;25(2):339-350. doi:10.1093/neuonc/noac173
BibTeX
@article{Lassman2023,
author = {Lassman, Andrew B and Pugh, Stephanie L and Wang, Tony J C and Aldape, Kenneth and Gan, Hui K and Preusser, Matthias and Vogelbaum, Michael A and Sulman, Erik P and Won, Minhee and Zhang, Peixin and Moazami, Golnaz and Macsai, Marian S and Gilbert, Mark R and Bain, Earle E and Blot, Vincent and Ansell, Peter J and Samanta, Suvajit and Kundu, Madan G and Armstrong, Terri S and Wefel, Jeffrey S and Seidel, Clemens and de Vos, Filip Y and Hsu, Sigmund and Cardona, Andrés F and Lombardi, Giuseppe and Bentsion, Dmitry and Peterson, Richard A and Gedye, Craig and Bourg, Véronique and Wick, Antje and Curran, Walter J and Mehta, Minesh P},
title = {Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial},
journal = {Neuro-Oncology},
year = {2023},
volume = {25},
number = {2},
pages = {339--350},
doi = {10.1093/neuonc/noac173}
}
EUVIMED